InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: blu_1 post# 112815

Wednesday, 07/26/2017 11:48:34 AM

Wednesday, July 26, 2017 11:48:34 AM

Post# of 464087
Inconsequential.

Now, come on. Just how could the apparently near-universal request for Anavex 2-73 dosing after the clinical trial ended by trial participants and their care givers be of any consequence?

After reading the multitude of so-helpful, definitive reports on this board, everyone knows that the extended post-trial Anavex 2-73 dosing requests were either a) plainly bogus, didn’t actually happen (more misinformation from the company or its supporters), or b) Australians simply have a stronger hope that something being tested on them might eventually work.

Here, we know for sure (Do we not?) that Anavex 2-73 simply did not and cannot produce relief from Alzheimer’s symptoms of any kind—no different from any of the dozen or so other candidate Alzheimer’s treatment drugs that have all failed.

Not only that, several posters here have questioned the exceptionally low incidence and weakness of the Anavex 2-73 adverse events (side effects) reported in the Australian study. Aren’t those Aussies hard to figure out? They had frequent and severe side effects (which Anavex conveniently didn’t properly report, using fragmentary statistics, it is supposed), but still, the Aussie trial participants universally begged the company to continue with the pills after the study anyway.

“Doc, during the study, I really felt like I was going to get better. I had lots of tummy and headaches after popping that pill each day, but I can handle it. Please, please, give me another 3-month’s supply. This is gotta work, somehow, someday. Now, where did I put my car keys?”

Just can’t figure out the Australian mind set, can we?

Or was this a very clever and devious selection process Anavex used, to enlist in their study only weak, easily-controlled minds, who could be subtly and surreptitiously persuaded to continue to beg for the pills after the trial.

Pretty clever, them Anavex clinical researchers. What a clever way to make blokes like us here think Anavex 2-73 really did suppress and reverse Alzheimer’s symptomatic progression.

Just like with the sneaky symptoms plot, we’ve been fooled again.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News